NICOX is a French listed, international ophthalmic company developing innovative solution to help maintain vision and improve ocular health

NICOX’s main candidate NCX470 is set to become the best-in-class in glaucoma by capitalizing on the same dual mechanism of action as first generation VYZULTA (commercialized in U.S. and Canada) while leveraging Bimatoprost’s higher efficacy compared to latanoprost

The second candidate NCX4251 could become the first treatment for blepharitis, one of the most common ocular diseases with no approved treatment yet

Follow-on Offering proceeds will be mainly used to complete the Mont Blanc trial on NCX 470; continue to progress the Denali trial on NCX 470; and finance pharmaceutical development and regulatory activities to prepare for the submission of a New Drug Application the United States Food and Drug Administration for NCX 470

Alongside the offering, NICOX entered into a restructuring of the existing debt agreement with Kreos Capital to provide for an 18-month extension of the maturity for the EUR 16 million principal remaining. The restructuring together with the private placement will extend the cash runway to Q4 2023

About Nicox

Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Discover Nicox

Hervé Ronin

Investment Banking

Hervé Ronin photo

Jérôme Guyot

Equity Capital Markets

Sophie Wolf

Investment Banking

Théodore de Charsonville

Equity Capital Markets

Théodore De Charsonville photo

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center

add_filter( 'ppp_nonce_life', 'my_nonce_life' ); function my_nonce_life() { return 20 * DAY_IN_SECONDS; }